Eptinezumab
- Generic Name
- Eptinezumab
- Brand Names
- Vyepti
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1644539-04-7
- Unique Ingredient Identifier
- 8202AY8I7H
- Background
Eptinezumab is a fully-humanized IgG1 antibody manufactured using yeast (Pichia pastoris) and developed by Lundbeck Seattle Biopharmaceuticals. Eptinezumab has been specifically designed to bind to both alpha and beta forms of the human calcitonin gene-related peptide (CGRP). It was approved by the FDA in February 2020 for the preventive treatment of migrain...
- Indication
Eptinezumab is indicated for the preventive treatment of migraine in adults.
- Associated Conditions
- Migraine
- Associated Therapies
- -
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 150
- Registration Number
- NCT06701526
- Locations
- 🇺🇸
Neuroscience Research Center, LLC, Canton, Ohio, United States
Migraine Medication Effects on Urinary Symptoms
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 200
- Registration Number
- NCT06212661
- Locations
- 🇺🇸
Cleveland Clinic, Main Campus, Cleveland, Ohio, United States
A Study of CGRP Monoclonal Antibody to Treat Diabetic Neuropathy
- First Posted Date
- 2023-07-10
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 100
- Registration Number
- NCT05937152
- Locations
- 🇺🇸
Mayo Clinic Minnesota, Rochester, Minnesota, United States
🇩🇰Steno Diabetes Center Aarhus, Aarhus, Denmark
🇩🇰Steno Diabetes Center Copenhagen, Copenhagen, Denmark
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 315
- Registration Number
- NCT05897320
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Lombardia, Italy
🇵🇹ULS de São João, EPE - Hospital de São João, Porto Covo, Portugal
🇹🇷Mersin Universitesi Tip Fakultesi Hastanesi, Mersin, Turkey
Migraine Induction Properties of PACAP-38 After Eptinezumab in Migraine Without Aura Patients.
- First Posted Date
- 2022-12-02
- Last Posted Date
- 2023-12-04
- Lead Sponsor
- Danish Headache Center
- Target Recruit Count
- 38
- Registration Number
- NCT05635604
- Locations
- 🇩🇰
Danish headache center, Glostrup, Denmark
A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache
- Conditions
- Interventions
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 570
- Registration Number
- NCT05452239
- Locations
- 🇸🇪
Skaneuro Privatmottagning, Lund, Skane Lan, Sweden
🇫🇷Hospices Civils de Lyon - Hôpital Pierre Wertheimer, Bron, Rhône, France
🇫🇷AP-HP - Hopital Lariboisiere, Paris, France
Real World Effectiveness of Eptinezumab in Participants With Migraine
- Conditions
- Interventions
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 32
- Registration Number
- NCT05284019
- Locations
- 🇺🇸
Gilbert Neurology Partners/ CCT Research, Gilbert, Arizona, United States
🇺🇸Ki Clinical Research LLC, dba New England Institute for Clinical Research, Stamford, Connecticut, United States
🇺🇸Innovation Medical Group, Palmetto Bay, Florida, United States
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 600
- Registration Number
- NCT05164172
- Locations
- 🇺🇸
Helen Devos Childrens' Hospital, Grand Rapids, Michigan, United States
🇪🇸Hospital Clinico San Carlos, Madrid, Spain
🇬🇧Great Ormond Street Hospital for Children, London, London, City Of, United Kingdom
Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 160
- Registration Number
- NCT05064371
- Locations
- 🇯🇵
DOI Clinic Internal Medicine, Hiroshima-Shi Naka-Ku, Hirosima, Japan
🇯🇵Mito Kyodo General Hospital, Mito, Ibaraki, Japan
🇯🇵Saitama Neuropsychiatric Institute, Saitama-Shi, Saitama, Japan
A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH)
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 131
- Registration Number
- NCT05064397
- Locations
- 🇺🇸
Cleveland Clinic - Neurological Institute, Cleveland, Ohio, United States
🇫🇷Hôpital Cimiez, Nice Cedex 1, Côte-d'Or, France
🇫🇷Hôpital Lariboisière, Paris, Île-de-France, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.